Astellas Pharma Inc. is a global pharmaceutical company headquartered in Tokyo, Japan, dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The company's business philosophy is to contribute to the health of people worldwide by discovering and developing innovative new medicines. Astellas focuses on therapeutic areas with high unmet medical needs, including Oncology, Urology, Immunology (including transplantation), Nephrology, and Neuroscience, as well as advancing new technological approaches and research into new modalities.
Serves as the global headquarters, overseeing strategic planning, corporate governance, global R&D direction, financial management, and worldwide operations.
Modern office facilities designed to foster collaboration and innovation, strategically located in Tokyo's business district.
Emphasis on scientific excellence, ethical conduct, patient-centricity ('Patient anshin'), and fostering a culture of open innovation. Collaborative environment with a focus on global teamwork.
Central hub for global decision-making, setting the company's long-term vision, and coordinating activities across all regions and functions.
Astellas Pharma Inc. operates globally with a significant presence in Japan, the Americas (North and South America), EMEA (Europe, Middle East, Africa), and Asia/Oceania. Key global functions supported include research and development (with major research sites in Japan and the U.S.), manufacturing facilities in several countries, and sales and marketing operations tailored to local markets worldwide. This extensive network enables Astellas to discover, develop, manufacture, and commercialize innovative treatments for patients across diverse geographies.
2-5-1, Nihonbashi-Honcho
Chuo-ku, Tokyo
Tokyo
Japan
Address: 1 Astellas Way, Northbrook, IL 60062, USA
Manages development, manufacturing, and commercialization of pharmaceutical products for the U.S. and broader Americas market, adapting global strategies to regional needs.
Address: 2000 Hillswood Drive, Chertsey, Surrey, KT16 0RS, UK
Drives commercial strategy, market access, and medical affairs for Astellas' portfolio within the EMEA region, ensuring compliance with diverse regulatory environments.
Address: 200 Middlefield Road, Suite 200, Markham, ON L3S 0C1, Canada
Focuses on bringing Astellas' innovative medicines to Canadian patients and healthcare providers, navigating the Canadian pharmaceutical landscape.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Astellas Pharma' leadership includes:
Astellas Pharma has been backed by several prominent investors over the years, including:
Astellas has seen key leadership transitions aimed at strengthening its strategic focus and commercial execution. Notable changes include appointments to Chief Commercial Officer and Chief Financial Officer roles.
Discover the tools Astellas Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Astellas Pharma Inc. primarily uses the 'first.last@astellas.com' email format for its employees globally. Variations may exist, but this is the most common structure.
first.last@astellas.com
Format
john.smith@astellas.com
Example
90%
Success rate
Astellas Pharma Inc. News • May 13, 2024
Astellas Pharma Inc. and Kelonia Therapeutics today announced a research collaboration and license agreement to develop novel immuno-oncology therapeutics. The collaboration will focus on generating innovative in vivo CAR T cell therapies for cancer....more
Astellas Pharma Inc. News • April 1, 2024
Astellas announced changes to its executive leadership effective April 1, 2024, including the appointment of Nick Lagunowich as Chief Commercial Officer and Claus Zieler as Chief Strategy Officer, alongside Minoru Ohta as Chief Financial Officer. These changes aim to accelerate growth and enhance strategic execution....more
Astellas Pharma Inc. News • February 5, 2024
Astellas announced that the U.S. Food and Drug Administration (FDA) approved VEOZAH™ (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. VEOZAH is the first and only nonhormonal neurokinin 3 (NK3) receptor antagonist approved to treat VMS due to menopause....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Astellas Pharma, are just a search away.